COMPARISON OF INTRACORONARY EPINEPHRINE TO STANDARD TREATMENTS ALONE FOR REFRACTORY CORONARY NO-REFLOW IN STEMI PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION

Refractory no-reflow is a serious primary percutaneous coronary intervention (PPCI) complication in ST-segment elevation myocardial infarction (STEMI) patients associated with worse clinical outcomes. Intracoronary epinephrine has been suggested as potential adjunctive therapy to improve perfusion these patients, but its efficacy and safety remain unclear. This study included 58 STEMI refractory during PPCI treated either intracoronary or conventional treatments alone. The outcome was the improvement assessed by TIMI frame count at end of procedure. Secondary outcomes rates adverse cardiovascular events 30 days. significantly improving compared alone (mean 24.1 ± 6.7 vs. 33.6 7.9, p < 0.001). benefit consistent across all subgroups 0-1 flow. Patients had lower days than those who received (12.5% 43.8%, = 0.02). two groups no significant differences major bleeding, recurrent infarction, all-cause mortality. Based on results, use improved events. These findings support safe effective this population, further studies are needed determine optimal dosing timing administration.